Top

Published in:

Open Access 01-12-2010 | Technical advance

Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma

Authors: Samaneh Boroumand-Noughabi, Hamid Reza Sima, Kamran Ghaffarzadehgan, Mostafa Jafarzadeh, Hamid Reza Raziee, Hanieh Hosseinnezhad, Omeed Moaven, Mohammad Taghi Rajabi-Mashhadi, Amir Abbas Azarian, Mojtaba Mashhadinejad, Jalil Tavakkol-Afshari

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Fas (Apo-1/CD95) and its specific ligand (FasL) are key elements in apoptosis. They have been studied in different malignancies but there are few published studies about the soluble forms of these markers (i.e. sFas/sFasL) in gastric cancer. We have compared the serum levels of sFas/sFasL in gastric adenocarcinoma patients and cases with pre-neoplastic lesions as potential markers for early diagnosis, and investigated their relation with clinicopathological characteristics.

Methods

Fifty-nine newly-diagnosed cases of gastric adenocarcinoma who had undergone gastrectomy, along with 62 endoscopically- and histologically-confirmed non-cancer individuals were enrolled in this study. sFas/sFasL serum levels were detected by Enzyme Linked Immunosurbent Assay.

Results

Mean serum sFas level was significantly higher in gastric cancer patients than in control group (305.97 ± 63.71 (pg/ml) vs. 92.98 ± 4.95 (pg/ml), P < 0.001); while the mean serum level of sFasL was lower in patients with gastric adenocarcinoma (0.138 ± 0.04 (pg/ml) vs. 0.150 ± 0.02 (pg/ml), P < 0.001). Mean serum levels of sFas/sFasL were significantly different in both intestinal/diffuse and cardiac/non-cardiac subtypes when compared to the control group (P < 0.001). There was an increase in the serum level of sFas from the first steps of pre-neoplastic lesions to gastric adenocarcinoma (P < 0.001). Patients who had no lymph node involvement (N ₀ ) showed significantly higher serum levels of sFas compared to others (P = 0.044).

Conclusions

Production of sFas may play a critical role in the carcinogenesis of intestinal-type gastric cancer. sFas serum level may serve as a non-invasive tool for early diagnosis of gastric cancer.

Available only for authorised users

Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005, 241 (1): 27-39.PubMedPubMedCentral

Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z: Cancer incidence and mortality in Iran. Ann Oncol. 2009, 20 (3): 556-563. 10.1093/annonc/mdn642.CrossRefPubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed

Reed JC: Apoptosis and cancer. Cancer medicine. Edited by: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr. 2003, Hamilton: BC Decker, 41-52. 6

Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001, 104 (4): 487-501. 10.1016/S0092-8674(01)00237-9.CrossRefPubMed

Krammer PH: CD95's deadly mission in the immune system. Nature. 2000, 407 (6805): 789-795. 10.1038/35037728.CrossRefPubMed

Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995, 373 (6513): 444-448. 10.1038/373444a0.CrossRefPubMed

Li-Weber M, Krammer PH: Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol. 2003, 15 (3): 145-157. 10.1016/S1044-5323(03)00030-7.CrossRefPubMed

Igney FH, Krammer PH: Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002, 71 (6): 907-920.PubMed

10.

Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995, 154 (6): 2706-2713.PubMed

11.

Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994, 263 (5154): 1759-1762. 10.1126/science.7510905.CrossRefPubMed

12.

Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K: Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer. 2000, 82 (8): 1446-1452.CrossRefPubMedPubMedCentral

13.

Bebenek M, Dus D, Kozlak J: Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat. Adv Med Sci. 2008, 53 (1): 49-53. 10.2478/v10039-008-0015-y.CrossRefPubMed

14.

Kamihira S, Yamada Y, Tomonaga M, Sugahara K, Tsuruda K: Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis. Br J Haematol. 1999, 107 (4): 851-860. 10.1046/j.1365-2141.1999.01792.x.CrossRefPubMed

15.

Tamakoshi A, Nakachi K, Ito Y, Lin Y, Yagyu K, Kikuchi S, Watanabe Y, Inaba Y, Tajima K: Soluble Fas level and cancer mortality: findings from a nested case-control study within a large-scale prospective study. Int J Cancer. 2008, 123 (8): 1913-1916. 10.1002/ijc.23731.CrossRefPubMed

16.

Bennett MW, O'connell J, O'sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F: Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999, 44 (2): 156-162.CrossRefPubMedPubMedCentral

17.

Li Z, Wang Z, Zhao Z, Zhang Y, Ke Y: [Expression of Fas, FasL and IFN-gamma in gastric cancer]. Beijing Da Xue Xue Bao. 2003, 35 (4): 386-389.PubMed

18.

Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y: Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol. 2003, 9 (7): 1415-1420.CrossRefPubMedPubMedCentral

19.

Ohno S, Tachibana M, Shibakita M, Dhar DK, Yoshimura H, Kinugasa S, Kubota H, Masunaga R, Nagasue N: Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol. 2000, 7 (10): 750-757. 10.1007/s10434-000-0750-1.CrossRefPubMed

20.

Ichikura T, Majima T, Uchida T, Okura E, Ogawa T, Mochizuki H: Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep. 2001, 8 (2): 311-314.PubMed

21.

Liang QL, Pan DC, Yin ZM, Liu GX, Yang Q, Xie JR, Cai LZ, Fu YW: [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. Ai Zheng. 2002, 21 (2): 174-176.PubMed

22.

Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T: Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer. 2000, 89 (12): 2560-2564. 10.1002/1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q.CrossRefPubMed

23.

Yatsuya H, Toyoshima H, Tamakoshi K, Tamakoshi A, Kondo T, Hayakawa N, Sakata K, Kikuchi S, Hoshiyama Y, Fujino Y, Mizoue T, Tokui N, Yoshimura T: Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor beta-1, soluble fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC Study. J Epidemiol. 2005, 15 (Suppl 2): S120-125. 10.2188/jea.15.S120.CrossRefPubMed

24.

Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996, 20 (10): 1161-1181. 10.1097/00000478-199610000-00001.CrossRefPubMed

25.

Bremer E, de Bruyn M, Wajant H, Helfrich W: Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family. Curr Drug Targets. 2009, 10 (2): 94-103. 10.2174/138945009787354593.CrossRefPubMed

26.

Rikhof B, van der Graaf WT, Meijer C, Le PT, Meersma GJ, de Jong S, Fletcher JA, Suurmeijer AJ: Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer. 2008, 99 (10): 1600-1606. 10.1038/sj.bjc.6604736.CrossRefPubMedPubMedCentral

27.

Li H, Liu N, Guo L, Li JW, Liu J: Frequent expression of soluble Fas and Fas ligand in Chinese stomach cancer and its preneoplastic lesions. Int J Mol Med. 2000, 5 (5): 473-476.PubMed

28.

Bellone G, Smirne C, Carbone A, Mareschi K, Dughera L, Farina EC, Alabiso O, Valente G, Emanuelli G, Rodeck U: Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. clin Cancer Res. 2000, 6 (6): 2448-2455.PubMed

29.

Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T: Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001, 92 (2): 287-293. 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4.CrossRefPubMed

30.

Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med. 1996, 2 (3): 317-322. 10.1038/nm0396-317.CrossRefPubMed

31.

Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002, 8 (8): 2553-2562.PubMed

32.

Yoshikawa T, Saito H, Osaki T, Matsumoto S, Tsujitani S, Ikeguchi M: Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer. J Surg Res. 2008, 148 (2): 143-151. 10.1016/j.jss.2007.07.011.CrossRefPubMed

33.

Kim R, Emi M, Tanabe K, Arihiro K: Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol. 2006, 7 (12): 1006-1016. 10.1016/S1470-2045(06)70975-5.CrossRefPubMed

34.

Kuo WH, Chen JH, Lin HH, Chen BC, Hsu JD, Wang CJ: Induction of apoptosis in the lung tissue from rats exposed to cigarette smoke involves p38/JNK MAPK pathway. Chem Biol Interact. 2005, 155 (1-2): 31-42. 10.1016/j.cbi.2005.04.008.CrossRefPubMed

35.

Park JW, Kim HP, Lee SJ, Wang X, Wang Y, Ifedigbo E, Watkins SC, Ohba M, Ryter SW, Vyas YM, Choi AM: Protein kinase C alpha and zeta differentially regulate death-inducing signaling complex formation in cigarette smoke extract-induced apoptosis. J Immunol. 2008, 180 (7): 4668-4678.CrossRefPubMed

36.

Imirzalioglu P, Uckan S, Alaaddinoglu EE, Haberal A, Uckan D: Cigarette smoking and apoptosis. J Periodontol. 2005, 76 (5): 737-739. 10.1902/jop.2005.76.5.737.CrossRefPubMed

37.

Sarafian TA, Tashkin DP, Roth MD: Marijuana smoke and Delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol Appl Pharmacol. 2001, 174 (3): 264-272. 10.1006/taap.2001.9224.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/275/prepub

Title: Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma
Authors: Samaneh Boroumand-Noughabi
Hamid Reza Sima
Kamran Ghaffarzadehgan
Mostafa Jafarzadeh
Hamid Reza Raziee
Hanieh Hosseinnezhad
Omeed Moaven
Mohammad Taghi Rajabi-Mashhadi
Amir Abbas Azarian
Mojtaba Mashhadinejad
Jalil Tavakkol-Afshari
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-275

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Defensin alpha 6 (DEFA 6) overexpression threshold of over 60 fold can distinguish between adenoma and fully blown colon carcinoma in individual patients

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age

Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo

Detection of HPV and the role of p16INK4Aoverexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer